Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues

Thrombosis and Haemostasis

Volumn 105, Issue 1, 2011, Pages 131-137

  Papachristopoulou, Georgia ^a,b   Avgeris, Margaritis ^a   Charlaftis, Antonios ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Oncology 6th IKA Hospital G Gennimatas   (Greece)

Author keywords

Biomarker; Breast cancer; Diagnosis; Kallikreins; KLK14

Indexed keywords

ESTROGEN RECEPTOR; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 14; MESSENGER RNA; PEPTIDASE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TUMOR VOLUME;

BIOPSY; BREAST NEOPLASMS; DNA, COMPLEMENTARY; FEMALE; HUMANS; KALLIKREINS; LOGISTIC MODELS; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 78651074964     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-02-0092     Document Type: Article

References (41)

1. Jemal A, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Krishnamurthy S, Sneige N. Molecular and biologic markers of premalignant lesions of human breast. Adv Anat Pathol 2002; 9: 185-197.
3. Stark A, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000; 18: 267-274.
4. Rohan TE, et al. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998; 90: 1262-1269.
5. Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am 2002; 29: 1-20.
6. Lundwall A, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387: 637-641.
7. Sotiropoulou G, et al. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009; 284: 32989-32994.
8. Diamandis EP. Prostate-specific Antigen: Its Usefulness in Clinical Medicine. Trends Endocrinol Metab 1998; 9: 310-316.
9. Black MH, et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumors and in normal breast secretions. Br J Cancer 2000; 82: 361-367.
10. Yu H, et al. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998; 4: 1489-1497.
11. Papachristopoulou G, et al. Expression analysis and study of KLK4 in benign and malignant breast tumors. Thromb Haemost 2009; 101: 381-387.
12. Li X, et al. Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies. Cancer Sci 2009; 100: 601-607.
13. Anisowicz A, et al. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996; 2: 624-636.
14. Talieri M, et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004; 91: 180-186.
15. Yousef GM, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat 2003; 78: 149-158.
16. Yousef GM, et al. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 2000; 69: 331-341.
17. Chang A, et al. Human kallikrein gene 13 (KLK13) expression by quantitative RTPCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer 2002; 86: 1457-1464.
18. Fritzsche F, et al. Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumor grades and positive nodal status. Br J Cancer 2006; 94: 540-547.
19. Yousef GM, et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer 2002; 87: 1294-1300.
20. Brattsand M, et al. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005; 124: 198-203.
21. Borgono CA, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003; 63: 9032-9041.
22. Yousef GM, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 2003; 119: 346-355.
23. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001; 56: 361-376.
24. Avgeris M, et al. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391: 505-511.
25. Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 2010; 6: 269-285.
26. Yousef GM, et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003; 56: 287-292.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
28. Thomadaki H, et al. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 2009; 101: 373-380.
29. Korbakis D, et al. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker. Clin Chem 2009; 55: 904-913.
30. Prezas P, et al. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 2006; 387: 807-811.
31. Schmitt M, Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost 2009; 101: 222-224.
32. Stavropoulou P, et al. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005; 357: 190-195.
33. Kishi T, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003; 63: 2771-2774.
34. Kountourakis P, et al. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb Haemost 2009; 101: 541-546.
35. Diamandis EP, et al. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000; 11: 54-60.
36. Soreide JA, et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 1992; 18: 112-118.
37. Vang R, Tavassoli FA. Risk for subsequent development of breast cancer. Am J Surg Pathol 2003; 27: 268-71; author reply 271-274.
38. Pike MC, et al. Estrogens, progestins, and risk of breast cancer. Ernst Schering Found Symp Proc 2007; 1:127-150.
39. Felber LM, et al. Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol Chem 2005; 386: 291-298.
40. Borgono CA, et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007; 282: 2405-2422.
41. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890.